BusinessWorld Online
Russian drugmaker seeks vaccine emergency use
Russia's Gamaleya Research Institute has applied for an emergency use authorization (EUA) for its Sputnik V vaccine in the Philippines.
The Philippine FDA received the application on January 7 and has asked Gamaleya to submit missing documents.
Gamaleya withdrew its application for clinical trials on January 6, opting instead to pursue EUA.
This decision, according to Science and Technology Undersecretary Rowena Guevarra, was made because EUA allows the vaccine to reach a broader population.
US drugmaker Pfizer and Britain's AstraZeneca have also filed for EUA in the Philippines.
Meanwhile, China's Sinopharm has yet to decide whether to pursue clinical trials or apply for EUA in the country.
🤖
This story was generated by AI to help you understand the key points. For more detailed coverage, please see the news articles from trusted media outlets below.
News Sources
See how different news organizations are covering this story. Below are the original articles from various Philippine news sources that contributed to this summary.
British pharmaceutical firm AstraZeneca has applied for emergency use authorization (EUA) for its COVID-19 vaccine in the Philippines, marking the second such application after Pfizer.
+1
Read more →
Chinese pharmaceutical company Sinovac has submitted an application for emergency use authorization (EUA) to the Philippine Food and Drug Administration (FDA).
Read more →
The Philippine FDA has approved Clover Biopharmaceuticals' application for Phase III clinical trials of its COVID-19 vaccine in the country.
Read more →
The Philippine Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to the Pfizer-BioNTech COVID-19 vaccine, making it the first to receive such approval in the country.
+2
Read more →
Sinopharm and Sinovac, two Chinese vaccine manufacturers, are expected to file for emergency use authorization (EUA) with the Philippine Food and Drug Administration (FDA) this week.
Read more →